




Title: UDP-glucuronosyltransferase1A4 polymorphisms in a 
Japanese population and kinetics of clozapine glucuronidation.  
 
Authors: Asami Mori, MD, Yoshihiro Maruo, MD, PhD, Masaru Iwai, 
MD, PhD, Hiroshi Sato, PhD, Yoshihiro Takeuchi, MD, PhD 
 
Affiliation: Department of Pediatrics (A.M., Y.M., M.I., Y.T.); and 
Bioscience (H.S.), Shiga University of Medical Science, Shiga, 
Japan 
 
 DMD Fast Forward. Published on February 11, 2005 as doi:10.1124/dmd.104.002576




Running title page 
 
Running title: UGT1A4 polymorphisms and their clozapine kinetics.  
Correspondence: Asami Mori, MD 
  Department of Pediatrics,  
  Shiga University of Medical Science, 
  Tsukinowa, Seta, Otsu, Shiga 520-2192, Japan 
  Phone: +81-77-548-2228   FAX: +81-77-548-2230 
  E-mail: asamim@belle.shiga-med.ac.jp 




No. of words: Abstract, 182 
  Introduction, 581 
  Discussion, 531 
Non-standard abbreviations: UDP; uridine diphosphate, PCR; 
polymerase chain reaction, SNP; single nucleotide polymorphism, 
CYP; cytochrome P450, TLC; thin layer chromatography, PVDF; 






 The UDP-glucuronosyltransferase (UGT) family plays a 
major role in the excretion of endobiotics and xenobiotics and their 
metabolites. Human UGT1A4 catalyzes the glucuronidation of 
primary, secondary and tertiary amines, sapogenins, androgens, 
and progestins. We directly sequenced PCR–amplified fragments of 
the UGT1A4 gene from 100 healthy adult Japanese volunteers, and 
calculated their mutation frequency.  We identified four single 
nucleotide polymorphisms (SNPs): three in exon 1 (142T>G: L48V, 
448T>C: L150L, 804G>A: P268P), and one in intron 1 
(867+43C>T). We found three types of alleles with distinct SNP 
combinations, that coded for different amino acid sequences: L48V-
L150L-P268P-867+43C>T (frequency, 0.155), L48V (0.01), and 
P268P (0.01) (wild type frequency was 0.825). The L48V mutant 
gave twice the efficiency (Vmax/Km) for the antipsychotic drug 
clozapine than the wild type. Efficiencies of L48V for trans-
androsterone, imipramine and cyproheptadine were increased, but 
the efficiency for tigogenin was reduced. L48V therefore increased 
or decreased the glucuronidation activity depending upon the 
substrates. This study shows the importance of identifying patients 
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with the L48V polymorphism when calculating dosage, and when 
considering the potential adverse effects of drugs that are substrates 






 The UDP-glucuronosyltransferase (UGT) superfamily plays 
a major role in the excretion of endobiotics and xenobiotics and their 
metabolites (Miners and Mackenzie, 1991). Its members have 
widely overlapping substrate specificity and characteristic individual 
tissue distribution. UGT comprises two sub-families, UGT1 and 
UGT2. UGT1 has a unique gene structure; there are thirteen exon 
1s from UGT1A1 to UGT1A13P, and exon 2 to 5 are used in 
common for all mRNAs expressed from the gene. Nine of these 
exon code for UGT1 isoforms (UGT1A1, UGT1A3, UGT1A4, 
UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10) 
(Mackenzie et al, 1997) and four code for pseudo exon 1s (UGT1BP, 
UGT1A11P, UGT1A12P, and UGT1A13P) (Gong et al., 2001). UGT1 
mRNAs are processed by differential splicing. The UGT1 gene 
appears to be structurally distinctive, in that the UGT1 proteins result 
from differential splicing of the divergent first exons, and share 
exons 2-5 in common (Ritter, 1992).  
A considerable number of UGT family polymorphisms exist. 
Human UGT1A1 polymorphisms have been studied particularly 
closely (Maruo et al., 1999), because they are the causes of 
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hereditary unconjugated hyperbilirubinemias (Bosma et al., 1992; 
Aono et al., 1993; Sato et al., 1996) and are risk factors for neonatal 
hyperbilirubinemia and breast milk jaundice (Maruo et al., 1999, 
2000). Polymorphisms of UGTs have also been found for UGT1A3 
(Iwai et al., 2004), UGT1A4 (Ehmer et al., 2004), UGT1A6  (Ciotti et 
al., 1997), UGT1A7 (Guillemette et al., 2000), UGT1A8 (Huang et 
al., 2002), UGT1A10 (Jinno et al., 2003), UGT2B4 (Levesque et al., 
1999), UGT2B7 (Jin et al., 1993), and UGT2B15 (Levesque et al., 
1997). 
Human UGT1A4, whose cDNA was first cloned by Ritter et 
al. (1991), has been identified in the human liver and stomach (King 
et al., 2000). It catalyzes glucuronidation of primary, secondary and 
tertiary amines, carcinogenic aromatic amines (ß-naphthylamine, 4-
aminobiphenyl, and benzidine), androgens, progestins, and plant 
steroids (hecogenin, diosgenin, and tigogenin) (Green et al., 1995 
Green and Tephly, 1996; King et al., 2000). UGT1A3 and UGT1A4 
catalyze the glucuronidation of important endogenous substances 
including amines and steroids (Mojarrabi et al., 1996; Green et al., 
1998). We have earlier described UGT1A3 polymorphisms in a 
Japanese population (Iwai et al., 2004).  UGT1A4 is 93% identical to 
UGT1A3, and catalyzes the glucuronidation of a number of clinically 
important therapeutic agents including antihistamines, tricyclic 
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antidepressants, and antipsychotics such as clozapine (8-chloro-11-
(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine).  
 Clozapine is known to undergo a large number of 
biotransformation reactions in humans (Dain et al., 1997).  Its 
metabolism is mediated by CYP1A2, CYP3A4 and CYP2D6 in the 
liver (Prior et al., 2003). When human liver microsomes are 
incubated with clozapine, at least 5% of the whole conjugates were 
the corresponding glucuronides (Breyer-Pfaff and Wachsmuth, 
2001). In experiments with expressed human UGT1A4, clozapine 
was mainly conjugated to tertiary 5-N-glucuronides, and to a lesser 
extent to a quaternary ammonium (Luo et al., 1994; Green et al., 
1995; Breyer-Pfaff and Wachsmuth, 2001).  Glucuronidation of 
clozapine by other UGT isoformes has not been studied, and its 
biotransformation routes have not been identified in full. The 
therapeutic serum concentration of clozapine as an antipsychotic 
drug exceeds 350 ng/ml, and in animal experiments its hepatic 
concentration was 20 times higher than in the blood (Gauch and 
Michaelis, 1971). Clozapine also has an adverse effect in 
agranulocytosis, which is assumed to be mediated by a chemically 
reactive metabolite (Pirmohamed et al., 1995; Breyer-Pfaff and 
Wachsmuth, 2001).  
Below, using clozapine as the substrate in gene expression 
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experiments, we analyzed the incidence and type of UGT1A4 








 [14C]UDP-glucuronic acid (15.5GBq/mmol) was obtained 
from Dupont-NEN (Wilmington, DE, USA), and UDP-glucuronic acid 
and clozapine, trans-androsterone (5α-androstan-3ß-ol-17-one), 
imipramine (10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-
propanamine hydrochloride), cyproheptadine (4-(5H-
dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine 
hydrochloride) and tigogenin ((25R)-5α-spirostan-3ß-ol) from Sigma-
Aldrich (St. Louis, MO, USA). A human liver cDNA library, Mutant Km 
Kit, and pkF18 vector were obtained from TaKaRa (Kyoto, Japan), 
and pCR2.1 vector, pCR3.1 vector, and TA cloning kit from 
Invitrogen (San Diego, CA, USA). The thin layer chromatography 
(TLC) plastic sheet 5748 used below was obtained from Merck 
(Darmstadt, Germany), the Gene PORTER transfection reagent 
from Gene Therapy Systems (San Diego, CA, USA), the PVDF 
membrane from BIO-RAD (Hercules CA, USA), and the ECL Plus 





Sequence analysis of UGT1A4 
 
 Genomic DNA was isolated from the leukocytes of 100 
healthy Japanese volunteers, with informed consent. The study was 
approved by the ethics committee of Shiga University of Medical 
Science. Exon 1 of UGT1A4, along with part of an intron, was 
amplified by PCR with primer pair 5’-TTTGTCTTCCAATTACATGC-
3’/ 5’-AGATATGGAAGCACTTGTAAG-3’. The forward primer was 
located upstream of the initiation codon, and the reverse primer was 
in the intron. The 1075-bp product was amplified by PCR under the 
following conditions: initial denaturing for 5 min at 94˚C, followed by 
1 min at 94˚C, 1 min at 62˚C, and 2 min at 72˚C for 30 cycles with a 
MiniCycler (MJ Research, USA).  A final reaction for 8 min at 72˚C 
ensured complete extension of the PCR products. The amplified 
DNA fragment sequences were determined directly with a 
dRhodamine terminator FS Ready Reaction Kit and PRISM 310 









Analysis of allelic polymorphisms 
 
  We subcloned the PCR products (40 ng) to pCR 2.1 vectors 
(50 ng) using a TA-cloning kit. Transformation by the ligated 
products took place using a Competent High JM109 (Toyobo, 
Osaka, Japan).  
 
Construction of expression vector 
 
 UGT1A4 DNA isolated from a human liver cDNA library was 
amplified by PCR with the primer pair. 5'-
TTTGTCTTCCAATTACATGC-3'/ 5'-AGATATGGAAGCACTTGTAAG-
3'. The cDNA was inserted into a pCR3.1 expression vector using a 
TA cloning kit. Mutation was induced by site-directed mutagenesis, 
using a Mutan Km Kit according to the manufacturer's instructions. 
The constructed cDNA was excised from the pCR3.1 vector by two 
restriction enzymes (Pst I and BamH I), and was ligated into a 
pkF18 vector (TaKaRa, Kyoto, Japan) for mutagenesis. To introduce 
the mutations, we used the following primer for the T to G 
transversion at nucleotide 142: 5’-
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AGCTCCCGCACGGCCTCCCGC-3’, where the mutation is 
indicated by underlining.  After the substitution had been introduced 
into the pkF18 vector, the converted cDNA was cut out and re-
ligated into the pCR3.1 vector. We checked the cDNA by 
sequencing. 
 
Expression of UGT1A4 in COS-7 cells 
 
 Twenty-four hours before transfection, 6 x105 COS-7 cells 
suspended in Dulbecco’s modified Eagle’s medium with 10% fetal 
bovine serum were seeded onto 100-mm-diameter culture plates. 
For transfection, 5ml of Dulbecco’s modified Eagle’s medium 
containing 50 µl GenePORTER and 3.0 µg DNA was poured onto 
the cells. Four hours later, 5 ml of Dulbecco’s modified Eagle’s 
medium containing 20% fetal bovine serum was added to each 
plate. Two models were generated–wild type UGT1A4 and L48V 
UGT1A4–and nontransfected cells were used as the controls. After 
48 hours, the transfected cells were harvested and stored at –80˚C 
prior to use.  Protein content was measured with a BCA Protein 
Assay Kit (Pierce, Rockford, IL).  
 




To preparation of a polyclonal antibody of UGT1A4, we 
chose a segment such that the amino acid sequence was unique 
among UGT1A4 isoforms and the mutation site (L48V) was 
excluded. We synthesized a 10-amino-acid segment 
(EHLLKRYSRS: residues 104-113) and generated its polyclonal 
antibody by immunizing rabbits. We purified the antibody by affinity 
chromatography of 18 ml of Thiol Sepharose 4B (Amersham 
Biosciences) coupled with 6 mg of the synthesized peptide. The 
column was equilibrated using Dulbecco's Phosphate Buffered 
Saline (Nacalai, Kyoto), and the antibody was eluted by 0.2 M-





 Cell homogenates underwent sodium dodesyl sulfate-
polyacrylamide gel electrophoresis. The protein was transferred to a 
PVDF membrane and visualized with ECL Plus Western blotting 
detection reagents. The membrane was incubated for 1 hour in 
blocking solution, 1 hour in a solution of anti-UGT1A4 antibody 
(1:500), and 1 hour in a solution of anti-rabbit antibody (1:15000). 
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The detection solution was added and the membrane was exposed 
to film for 5 min.  The relative amounts of UGT1A4 expressed at the 
protein band peaks were measured with an Image Master-CL 
(Amersham Biosciences, Uppsala, Sweden). We blotted the wild 
type and L48V samples as a pair on the same membrane, and 
confirmed the measurements were in the linear range by assaying 
three different concentrations of an identical cell homogenate at the 
same time. The relative amount of L48V UGT1A4 was always within 
about 0.9-1.1 times that of wild type UGT1A4.   
 
Assay of UGT1A4 activity 
 
  UGT1A4 activity was assayed as described previously, with 
a minor modification (Iwai et al., 2004). The glucuronidation process 
of the substrate was assayed with [14C]UDP-glucuronic acid. The 
incubation mixture contained cell homogenate (100-150µg), 
clozapine (0-500µM), UDP-glucuronic acid (500µM), 9.25 kBq 
[14C]UDP-glucuronic acid (5.97µM), DMSO (1%), MgCl2 (10mM), 
50mM Tris-HCl buffer (pH 8.4), and saccharolactone (8.5mM) in a 
final volume of 100 µl. Incubation took place at 37˚C for 30 min. The 
clozapine-glucuronide that resulted was isolated by thin layer 
chromatography (TLC) on TLC plastic sheet 5748. The TLC plates 
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were developed in a solvent system containing n-butanol, acetone, 
water, and ammonium hydroxide (35:35:20:10, v/v), and were 
scanned on an Instant Imager (Packard, Meriden, CT). Major and 
minor glucuronide metabolites of clozapine were detected, and their 
combined density was taken to represent the reaction product. 
 Under the same conditions, we measured the UGT1A4 
activities of the wild type and L48V, using as substrates trans-
androsterone (0-500µM), a tricyclic antidepressant, imipramine  (0-
500µM), an antihistamine, cyproheptadine (0-500µM), and tigogenin 




 We calculated kinetic parameters using the Prism 3.0 
software (Graph Pad Software, Inc., San Diego, CA, USA) and non-
linear regression on the Michaelis-Menten equation. All data 
displayed are the means of three separate experiments. The 








Identification of UGT1A4 mutations and their frequencies  
 
 We identified three nucleotide substitutions in exon 1 of 
UGT1A4 in our Japanese test population. One was a T to G 
transversion at nucleotide position 142 (142T>G), that predicted a 
substitution of valine for leucine at codon 48 of the enzyme (L48V). 
The other two were novel, silent transitions (448T>C: L150L, 
804G>A: P268P).  We identified a novel substitution mutation in the 
intron (867+43C>T) and found no substitutions in exons 2-5. The 
incidence of the substitutions identified ranged from 0.155 to 0.165 
(Table 1), indicating that they represented polymorphisms in the 
sample population. Indeed, analysis of subcloned exon 1 revealed 
the presence of four alleles, with frequencies ranging from 0.01 to 
0.825 (Fig.1). Two of these (L48V-L150L-P268P-867+43C>T and 
P268P) were novel.  We detected 5 patterns of allelic combinations 
(Fig.2).  
  




In a Western blotting analysis, 55-kDa protein bands (Fig.3) 
(Miners and Mackenzie, 1991) were detected in all the expression 
models but not in the mock transfection; the molecular weight of the 
band was as reported previously.  
 
Activities of UGT1A4 isoforms 
  
 Clozapine-glucuronide production was proportional to the 
amount of cell homogenate at up to 1000 µg. At 100 µg, the reaction 
product was linear with time up to 90 min. The reaction velocity 
increased steeply with pH and then reached a plateau at pH8.0-9.0. 
Lineweaver-Burk plots showed the apparent Km of the reaction to 
be 285µM at three clozapine concentrations (25µM, 50µM, and 
200µM), and 66µM at three UDP-glucuronic acid concentrations 
(125µM, 250µM, and 500µM).  
 At about 200µM clozapine, glucuronidation by wild type 
UGT1A4 reached its maximum velocity and then declined, indicating 
substrate inhibition (Fig.4). Table 2 shows the kinetic parameters of 
the expressed wild type and L48V enzymes. The difference in Vmax 
between these was not statistically significant, and the Km of L48V 
was half that of the wild type enzyme, implying that the relative 
efficiency (Vmax/Km) of the homozygous model of L48V was twice 
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that of the wild type.  
 Table 3 shows kinetic parameters determined for UGT1A4 for 
trans-androsterone substrate, compareing that type for which the 
glucuronidation activity decreased in L48V with the wild type (Ehmer 
et al., 2004); comparisons are also presented for three other 
substrates, imipramine, cyproheptadine and tigogenin. The L48V 
had only 30-60% of Vmax value of the wild type for all four 
substrates. Apparent Km values of L48V for trans-androsterone, 
imipramine and cyproheptadine were also considerably smaller than 
for the wild type, but that of tigogenin was not changed. The 
L48V/wild ratios of efficiencies for trans-androsterone, imipramine, 







 Glucuronidation is a major excretion pathway for diverse 
endobiotics and xenobiotics catalyzed by the UGT family of 
enzyme. A considerable number of UGT polymorphisms have been 
identified, some of which are associated with disease or adverse 
drug effects. Polymorphisms of UGT1A1 are known to cause 
Gilbert syndrome, a mild hereditary unconjugated 
hyperbilirubinemia, breast milk jaundice (Maruo et al. 2000), and 
may contribute to breast cancer (Adegoke et al. 2004).  
Polymorphisms of UGT1A4, UGT1A6, UGT1A7, and UGT1A8 may 
also be risk factors for carcinogenesis (Ehmer et al., 2004; Gagne 
et al., 2002; Strassburg et al., 2002). In our previous report we 
detected six novel UGT1A3 SNPs and considered their possible 
contribution to differences between individuals in drug metabolism 
and susceptibility to side effects (Iwai et al., 2004). UGT1A4 has a 
fairly similar amino acid sequence to UGT1A3 and overlapping 
substrate specificity for several amines, suggesting the presence of 
its polymorphism.  
  In the experiments reported here, we analyzed UGT1A4 in 
our Japanese test population. We identified two novel and one 
known single nucleotide substitution in exon 1, and one novel 
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substitution in intron 1 (Table 1).  All incidences were greater than 
0.01, indicating that the substitutions were polymorphisms. Recently, 
P24T and L48V polymorphisms have been detected in a Caucasian 
population in Germany  (Ehmer et al., 2004).  We did not detect 
P24T in our sample population, but L48V is a common 
polymorphism in Japanese as well as European populations. The 
present analysis showes that polymorphism of UGT1A4 differs 
between races. 
 Linkage analysis of the alleles coded by the four UGT1A4 
SNPs revealed that their combinations generate three 
polymorphisms (Fig. 2), of which two (L48V-L150L-P268P-867 
+43C>T and P268P) are novel. The amino acid sequence of the 
enzymes expressed by L48V-L150L-P268P-867 +43C>T and L48V 
were the same, but the former had an additional intronic 
polymorphism (867 +43C>T). Thus, based on amino acid 
sequences, there were only two enzymes in the sample population–
wild type and L48V.  The location of 867 +43C>T in the first intron 
was not in the typical consensus sequence of splicing, and the 
nature of its contribution, in the splicing of UGT1A4 mRNA is not 
clear. 
  In the present study, L48V was twice as efficient as the wild 
type in glucuronidating the antipsychotic drug clozapine (Table 2). 
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We also confirmed, by in vitro expression of the wild type enzyme, 
that the glucuronidation of clozapine shows substrate inhibition 
(Fig.4). Ehmer et al. (2004) reported that the L48V activity for trans-
androsterone was lower than the wild type. Although our date also 
found a reduced Vmax of L48V for trans-androsterone (Table 3), the 
efficiency of L48V was 10 times higher than that of the wild type. 
Likewise, the efficiencies of L48V for imipramine and 
cyproheptadine were 1.6 – 1.8 times higher than that of the wild 
type, but that for tigogenin there was reduction by a factor of 0.6. 
These results indicate that L48V accelerates or slows the 
glucuronidation of UGT1A4, depending on substrates.  
In conclusion, our results find a polymorphism of UGT1A4 
(L48V) in Japanese population. An understanding of the effects of 
the mutation on the glucuronidation of substrate drugs would help 
clinicians who prescribe these drugs to calculate the appropriate 
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Legends for figures 
 
Fig. 1 Amino acid substitutions found in UGT1A4 in the Japanese 
population sample, and their frequencies. 
 
Fig. 2 Amino acid substitution combinations found in UGT1A4 in the 
Japanese population sample, and their frequencies.  
 
Fig. 3 Identification of expressed UGT1A4 protein by Western 
blotting.  
A, Mock transfection; B, Wild type; C, L48V.  
 
Fig. 4 Velocity of reaction of wild type UGT1A4 with clozapine.  The 
reaction mixture contained 100 µg cell homogenate and 500 µM 
UDP-glucuronic acid, and was incubated for 30 min at pH 8.4. Note 


















142 exon 1 T G L48V 0.165 
448 exon 1 T C L150L (silent) 0.155 
804 exon 1 G A P268P (silent) 0.165 














Wild type 1205±168.0 49.18±13.9 25.4±4.80 
L48V 1315±246.8 25.41±5.05 52.7±13.1c 
aVmax: maximum velocity 
bKm: Michaelis constant 





Table 3 Kinetic parameters of wild type and L48V UGT1A4 for trans-androsterone, 
imiramine, cyproheptadine and tigogenin. 
  
Substrate  Wild type L48V 
Trans-androsterone Vmaxa (pmol/min/mg) 107.3 35.7 
 Km
b (µM) 254.7 8.2 
Imipramine Vmax (pmol/min/mg) 872.8 294.9 
 Km (µM) 1442.0 275.8 
Cyproheptadine Vmax (pmol/min/mg) 342.6 203.3 
 Km (µM) 227.5 86.4 
Tigogenin Vmax (pmol/min/mg) 158.6 81.4 
 Km (µM) 7.8 6.7 
 
aVmax: maximum velocity 
bKm: Michaelis constant 
 




